BridgeBio Pharma (BBIO) Cash from Operations (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -249.66% |
| Dec 31, 2025 | 48.51% |
| Sep 30, 2025 | -35.81% |
| Jun 30, 2025 | 59.50% |
| Mar 31, 2025 | -2.00% |
| Dec 31, 2024 | -8.17% |
| Sep 30, 2024 | -341.71% |
| Jun 30, 2024 | 134.03% |
| Mar 31, 2024 | -75.88% |
| Dec 31, 2023 | 14.05% |
| Sep 30, 2023 | -28.12% |
| Jun 30, 2023 | 21.46% |
| Mar 31, 2023 | -54.78% |
| Dec 31, 2022 | 31.01% |
| Sep 30, 2022 | -343.84% |
| Jun 30, 2022 | 81.04% |
| Mar 31, 2022 | -19.97% |
| Dec 31, 2021 | -10.15% |
| Sep 30, 2021 | -32.55% |
| Jun 30, 2021 | 39.17% |
| Mar 31, 2021 | -56.62% |
| Dec 31, 2020 | 26.90% |
| Sep 30, 2020 | -49.90% |
| Jun 30, 2020 | -4.68% |
| Mar 31, 2020 | -10.13% |
| Dec 31, 2019 | -52.42% |
| Sep 30, 2019 | 26.74% |
| Jun 30, 2019 | -15.40% |
| Mar 31, 2019 | -27.42% |
| Dec 31, 2018 | -21.12% |